Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: Identification of new signaling elements

Molecular Carcinogenesis

Volumn 48, Issue 3, 2009, Pages 220-231

  Gorla, L ^a   Mondellini, P ^a   Cuccuru, G ^a   Micciche F ^a   Cassinelli, G ^a   Cremona, M ^a   Pierotti, M A ^a,b   Lanzi, C ^a   Bongarzone, I ^a,c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c NONE   (Italy)

Author keywords

EGFR; LGALS3BP; Medullary thyroid carcinoma; RET oncogenic signaling; Tyrosine phosphorylation

Indexed keywords

1,3 DIHYDRO 5,6 DIMETHOXY 3 [(4 HYDROPHENYL)METHYLENE]1 H INDOL 2 ONE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MESSENGER RNA; ONCOPROTEIN; PHOSPHOTYROSINE; PROTEIN TYROSINE KINASE INHIBITOR; RPI 1; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR; PROTEIN RET; QUINAZOLINE DERIVATIVE; RET PROTEIN, HUMAN; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GERM LINE; HUMAN; HUMAN CELL; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; MEDULLARY CARCINOMA; METABOLISM; MUTATION; NUDE MOUSE; PHOSPHORYLATION; THYROID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, MEDULLARY; EPIDERMAL GROWTH FACTOR; FEMALE; GERM-LINE MUTATION; HUMANS; MICE; MICE, NUDE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; ONCOGENE PROTEINS; PHOSPHORYLATION; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-RET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TYROSINE;

EID: 62349122222     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20474     Document Type: Article

References (41)

1. Marsh DJ, Learoyd DL, Andrew SD, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol 1996;44:249-257.
2. Stephen JM. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 2005;5:367-375.
3. Schilling T, Buck J, Sinn HP, et al. Prognostic value of codon 918 (ATG->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 2001;95: 62-66.
4. Songyang Z, Carraway KL III, Eck MJ, et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 1995;375:536-539.
5. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Ann Rev Biochem 2000;69:373-398.
6. Iwashita T, Kato M, Murakami H, et al. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene 1999;18: 3919-3922.
7. Gujral TS, Singh VK, Jia Z, Mulligan LM. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia2B. Cancer Res 2006;66: 10741-10749.
8. Jain S, Watson MA, DeBenedetti MK, et al. Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors. Cancer Res 2004;64:3907-3913.
9. Drosten M, Putzer BM. Mechanisms of disease: Cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat Clin Pract Oncol 2006;3: 564-574.
10. De Groot JW, Links TP, Plukker JT, et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006;27:535-560.
11. Asai N, Jijiwa M, Enomoto A, et al. RET receptor signaling: Dysfunction in thyroid cancer and Hirschsprung's disease. Pathol Int 2006;56:164-172.
12. Lanzi C, Cassinelli G, Cuccuru G, et al. Inactivation of Ret/ Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sc 2003;60:1449-1459.
13. Carniti C, Perego C, Mondellini P, et al. PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting. Cancer Res 2003;63:2234-2243.
14. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-7290.
15. Petrangolini G, Cuccuru G, Lanzi C, et al. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1. Biochem Pharmacol 2006;72:405-414.
16. Cuccuru G, Lanzi C, Cassinelli G, et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 2004;96:1006-1014.
17. Lanzi C, Cassinelli G, Pensa T, et al. Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative. Int J Cancer 2000;85:384-390.
18. Shah SR, Pharm D. Gefitinib (ZD1839, Iressa®): A selective epidermal growth factor receptor-tyrosine kinase inhibitor. J Oncol Pharm Pract 2003;9:151-160.
19. Gorla L, Cantu M, Micciche' F, et al. RET oncoproteins induce tyrosine phosphorylation changes of proteins involved in RNA metabolism. Cell Signal 2006;18:2272-2282.
20. Borrello MG, Alberti L, Arighi E, et al. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site or phospholipase Cgamma. Mol Cell Biol 1996;16:2151-2163.
21. Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 2001;12:361-373.
22. Hellstern S, Sasaki T, Fauser C, et al. Functional studies on recombinant domains of Mac-2-binding protein. J Biol Chem 2002;277:15690-15696. .
23. Bongarzone I, Vigano E, Alberti L, et al. Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation. Oncogene 1998;16:2295-2301.
24. Blagoev B, Ong SE, Kratchmarova I, Mann M. Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics. Nat Biotechnol 2004;22:1139-1145.
25. Thelemann A, Petti F, Griffin G, et al. Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Mol Cell Proteomics 2005;4:356-376.
26. Zhang Y, Wolf-Yadlin A, Ross PL, et al. Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signalling network reveals dynamic modules. Mol Cell Proteomics 2005;4:1240-1250.
27. Inberg A, Bogoch Y, Bledi Y, Linial M. Cellular processes underlying maturation of P19 neurons: Changes in protein folding regimen and cytoskeleton organization. Proteomics 2007;7:910-920.
28. Stern KA, Visser Smit GD, Place TL, et al. Epidermal growth factor receptor fate is controlled by Hrs tyrosine phosphorylation sites that regulate Hrs degradation. Mol Cell Biol 2007;27:888-898.
29. Rush J, Moritz A, Lee KA, et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 2005;23:94-101.
30. Dromard M, Bompard G, Glondu-Lassis M, et al. The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation. Cancer Res 2007;67:6806-6813.
31. Laurent CE, Delfino FJ, Cheng HY, Smithgall TE. The human c-Fes tyrosine kinase binds tubulin and microtubules through separate domains and promotes microtubule assembly. Mol Cell Biol 2004;24:9351-9358.
32. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006;18: 516-523.
33. Iacobelli S, Arnò E, D'orazio A, Coletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res 1986;46:3005-3010.
34. Koths K, Taylor E, Halenbeck R, et al. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem 1993; 268:14245-14249.
35. Resnick D, Pearson A, Krieger M. The SRCR superfamily: A family reminiscent of the Ig superfamily. Trends Biochem Sci 1994;19:5-8.
36. Iacobelli S, Sismondi P, Giai M, et al. Prognostic value of a novel circulating serum 90 K antigen in breast cancer. Br J Cancer 1994;69:172-176.
37. Ochwat D, Hoja-Lukowicz D, Litynska A. N-glycoproteins bearing beta1-6 branched oligosaccharides from the A375 human melanoma cell line analysed by tandem mass spectrometry. Melanoma Res 2004;14:479-485.
38. Marchetti A, Tinari N, Buttitta F, et al. Expression of 90 K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res 2002;62:2535-2539.
39. Yabana N, Shibuya M. Adaptor protein APS binds the NH2-terminal autoinhibitory domain of guanine nucleotide exchange factor Vav3 and augments its activity. Oncogene 2002;21:7720-7729.
40. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994;77:841-852.
41. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16.